Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

What Was Tested

The paper reports a study of Amylin (Islet Amyloid Polypeptide) and Petrelintide, published as a randomized controlled trial.

Petrelintide is a long-acting amylin analogue in development for weight management.

Who Took Part

The study group was 2 adults.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The SAD and MAD part 1 trials enrolled normal or overweight adults; MAD part 2 enrolled adults with overweight or obesity.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Amylin (Islet Amyloid Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the adults nor the staff measuring them knew who was on Amylin (Islet Amyloid Polypeptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Amylin (Islet Amyloid Polypeptide) could be set against what happens without it.

Both trials were randomized, placebo-controlled, and double-blind.

What Was Measured

PubMed files the paper under topics including Obesity, Anti-Obesity Agents, Islet Amyloid Polypeptide, Overweight and Weight Loss.

Author keywords: antiobesity drug, clinical trial, obesity therapy, phase I‐II study and weight management.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Amylin (Islet Amyloid Polypeptide) and Petrelintide in 2 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page and the Petrelintide compound page, all human trials.